INDP Indaptus Therapeutics
- 0.836
- -0.014-1.66%
- 0.836
- 0.0000.00%
Indaptus Therapeutics News
Maxim Group Maintains Indaptus Therapeutics(INDP.US) With Buy Rating, Cuts Target Price to $5
Indaptus Therapeutics Analyst Ratings
Maxim Group Maintains Indaptus Therapeutics(INDP.US) With Buy Rating, Cuts Target Price to $5
Maxim Group Maintains Indaptus Therapeutics(INDP.US) With Buy Rating, Maintains Target Price $8
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
Indaptus Therapeutics Analyst Ratings
Maxim Group Maintains Indaptus Therapeutics(INDP.US) With Buy Rating, Maintains Target Price $8
Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Decoy20 Clinical Developments
Indaptus Therapeutics Expects Cash and Cash Equivalents Will Support Operating Activities Into 1Q 2025 >INDP
Indaptus Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cingulate Inc (CING), Indaptus Therapeutics (INDP) and Immunocore Holdings (IMCR)
Buy Rating Affirmed for Indaptus Therapeutics Amid Promising Decoy20 Clinical Advancements
HC Wainwright & Co. : Indaptus Therapeutics (INDP.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.
Indaptus Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
Buy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough With Decoy20 Platform
Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial Outlook
Buy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 With Promising Developments
Analysts Conflicted on These Healthcare Names: Ventyx Biosciences (VTYX) and Indaptus Therapeutics (INDP)
No Data